Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization in China from National Medical Products Administration (NMPA) for the ...

Creative Diagnostics, a leading manufacturer and supplier of antibodies, small molecule conjugates and critical assay ...

Discover how ADCs are advancing oncology, the regulatory challenges they face, and the promise they hold for the future of ...

Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies ...

The global legionnaire disease testing market is on the verge of remarkable expansion, with projections forecasting a ...

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...

An expert highlighted unmet needs in treating T-cell acute lymphoblastic leukemia and where research may focus in the future.

The Swiss pharma group has agreed a $9 per share deal to acquire Poseida, valuing the company at around $1 billion, with another $500 million potentially payable to shareholders in a contingent value ...

The company, based outside of Grenoble in the French Alps, together with its partners has received €5 million to pursue the project.